Webinar to be Held December 6, 2023 at 1:30pm EST AUSTIN, Texas — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results...
treatment News
Austin, Texas — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in Oppenheimer’s 33rd Annual Healthcare Conference held virtually March 13-15, 2023. Lumos Pharma will present and host virtual one-on-one...
SEOUL, South Korea — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study featuring Lunit SCOPE IO, Lunit’s AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international...
Chicago, Illinois – On March 27, 2024, Ann & Robert H. Lurie Children’s Hospital of Chicago treated its first patient with ELEVIDYS (delandistrogene moxeparvovec-rokl), the first gene therapy for Duchenne muscular dystrophy – a rare, genetic disease characterized by progressive muscle damage and weakness. Lurie Children’s is the first in...
Lyme disease is emerging in Canada, and is expected to increase with climate change, but effective, enhanced surveillance and clinician awareness will be key to minimizing the impact of the disease, write researchers in a review in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/press/pg1221.pdf (www.cmaj.ca). Lyme disease is transmitted by ticks...
WATERTOWN, Mass. — Lyndra Therapeutics®, a clinical-stage biopharmaceutical company, today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the pharmacokinetic (PK) profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder. The STARLYNG-1 study is designed to bridge to the...
Lysogene (Paris:LYS) (FR0013233475 – LYS), a gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its LYS-GM101 program, which is being studied in the recently initiated global adaptative-design clinical trial for the treatment...
Lysogene (Paris:LYS) (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced dosing of the first patient, at Royal Manchester Children’s Hospital, part of Manchester University NHS Foundation Trust, in the global adaptative-design clinical trial with LYS-GM101 (NCT04273269), a gene therapy for...
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced dosing of the first patient in the United States (second patient in the global adaptative-design clinical trial) with LYS-GM101 investigational gene therapy at CHOC Hospital (CHOC) in a global adaptative-design...
LYON, France – MaaT Pharma announced today that final results from its Phase 1/2 ODYSSEE clinical trial have been published in the journal, Nature Communications. The data demonstrated that the company’s initial product candidate, MaaT011, an autologous fecal microbiota transfer treatment, was safe and effective in fully restoring the gut microbiota in the...